Biotech Values

[ariadndndough]

From LR today. Interesting approval notice indicated ~50%+ PDL1 expression patients, language in the label suggests that it can be used for all PDL1 positive patients, no matter the expression level – the determination will be left to the physicians and not solely on the diagnostic. Seamus Fernandez spoke to MRK management who confirmed all PDL1 positive patients, and this is now a broader label than expected by the Street